Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Liver disease in cystic fibrosis.

Literature DB >> 7539244

Liver disease in cystic fibrosis.

M S Tanner¹, C J Taylor.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1995 PMID： 7539244 PMCID： PMC1511230 DOI： 10.1136/adc.72.4.281

Source DB: PubMed Journal: Arch Dis Child ISSN： 0003-9888 Impact factor: 3.791

× No keyword cloud information.

39 in total

1. Defective beta-adrenergic secretory responses in submandibular acinar cells from cystic fibrosis patients.

Authors: M A McPherson; R L Dormer; N A Bradbury; J A Dodge; M C Goodchild
Journal: Lancet Date: 1986-11-01 Impact factor: 79.321

2. Cystic fibrosis gene and mucin secretion.

Authors: M A McPherson; R L Dormer
Journal: Lancet Date: 1994-01-01 Impact factor: 79.321

3. Liver transplantation for hepatic cirrhosis in cystic fibrosis.

Authors: G Noble-Jamieson; J Valente; N D Barnes; P J Friend; N V Jamieson; A Rasmussen; R Y Calne
Journal: Arch Dis Child Date: 1994-10 Impact factor: 3.791

4. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis.

Authors: G N Thompson
Journal: J Pediatr Gastroenterol Nutr Date: 1988 Mar-Apr Impact factor: 2.839

5. Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line.

Authors: M Strazzabosco; C Poci; C Spirlí; L Sartori; A Knuth; G Crepaldi
Journal: Hepatology Date: 1994-01 Impact factor: 17.425

6. Analysis of risk factors for the development of liver disease associated with cystic fibrosis.

Authors: C Colombo; M G Apostolo; M Ferrari; M Seia; S Genoni; A Giunta; L P Sereni
Journal: J Pediatr Date: 1994-03 Impact factor: 4.406

7. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.

Authors: V Simko; S Michael; V Prego
Journal: Am J Gastroenterol Date: 1994-03 Impact factor: 10.864

8. Ursodeoxycholic acid reduces the systemic toxicity of 1,2-dichloro,4-nitrobenzene by stimulating hepatic glutathione S-transferase in mice.

Authors: K Kitani; S Kanai; Y Sato; M Ohta; M Nokubo
Journal: Life Sci Date: 1994 Impact factor: 5.037

Review 8. Aetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factors.

Authors: Sabina Więcek; Halina Woś; Urszula Grzybowska-Chlebowczyk
Journal: Prz Gastroenterol Date: 2013-10-28

8 in total

Liver disease in cystic fibrosis.

1. Defective beta-adrenergic secretory responses in submandibular acinar cells from cystic fibrosis patients.

2. Cystic fibrosis gene and mucin secretion.

3. Liver transplantation for hepatic cirrhosis in cystic fibrosis.

4. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis.

5. Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line.

6. Analysis of risk factors for the development of liver disease associated with cystic fibrosis.

7. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.

8. Ursodeoxycholic acid reduces the systemic toxicity of 1,2-dichloro,4-nitrobenzene by stimulating hepatic glutathione S-transferase in mice.

9. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease.

10. Bile acid secretion in cystic fibrosis: evidence for a defect unrelated to fat malabsorption.

Review 1. The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease.

2. Annual review or continuous assessment?

3. A new metabolomics analysis technique: steady-state metabolic network dynamics analysis.

4. Retrospective review of cystic fibrosis presenting as infantile liver disease.

5. The evolution of liver disease in cystic fibrosis.

Review 6. The gallbladder and biliary tract in cystic fibrosis.

Review 7. Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.

Review 8. Aetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factors.